Expression of pp32 in human benign prostatic hyperplasia and prostatic adenocarcinoma

S. S. Kadkol, J. M. Rebel, J. R. Brody, F. P. Kuhajda, G. R. Pasternack

Research output: Contribution to journalArticlepeer-review


pp32 is a nuclear phosphoprotein expressed in self-renewing and neoplastic cells. Paradoxically, pp32 both inbibits transformation and confers resistance to drug-induced apoptosis, suggesting differential actions, possibly through mutation, in normal and neoplastic cells. We studied pp32 expression in human prostatic adenocarcinoma and benign prostatic hyperplasia (BPH) by in situ hybridization using digoxigenin-labeled RNA probes. In BPH, pp32 expression localized only to basal cells in benign glands. Prostatic intraepithelial neoptasia (PIN) showed moderate pp32 expression. Primary prostatic adenocarcinomas showed pp32 expression in 10/11 cases with increased prevalence in Gleason grade adenocarcinomas greater than grade 5, although accompanied by substantial heterogeneity in expression level. Locally aggressive adenocarcinomas showed higher expression levels than tumors without those features (p<0.05). We conclude that aberrant pp32 expression in PIN, increased prevalence of expression in higher Gleason grade prostatic adenocarcinomas and expression in clinically aggressive tumors suggests a role for pp32 in tumor progression in prostatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)905-913
Number of pages9
JournalCancer Molecular Biology
Issue number5
StatePublished - 1996
Externally publishedYes


  • in situ hybridization
  • mRNA
  • non-isotopic
  • nuclear proteins
  • prostate cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Oncology
  • Cancer Research


Dive into the research topics of 'Expression of pp32 in human benign prostatic hyperplasia and prostatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this